Remixtherapeutics
Director, Commercial Project Management & Launch Excellence
Watertown, MA . Posted 19 days ago
The role
The Director will translate commercial strategy into an actionable enterprise launch plan. This person will lead the integrated planning, coordination, execution, and tracking of the potential launch of REM-422.
What you will do
- Build and maintain the integrated launch roadmap.
- Partner with leaders to translate launch objectives into functional plans.
- Establish fit-for-purpose launch governance and cross-functional launch teams.
- Lead focused meetings with clear agendas and follow-up actions.
- Provide concise leadership updates on readiness and critical dependencies.
- Build productive relationships across internal teams and external partners.
- Implement practical project management standards, templates, and dashboards.
- Maintain an integrated register of risks, assumptions, issues, and dependencies.
- Assist in readiness reviews and launch simulations.
Required qualifications
- Bachelor’s degree in life sciences, business, or a related discipline, or equivalent relevant experience.
- 10 or more years of relevant experience in biotechnology or pharmaceuticals.
- Substantial responsibility for commercial project management, launch readiness, or cross-functional program leadership.
- Understand the sequence and dependencies of commercialization.
- Apply integrated scheduling, critical path analysis, capacity planning, change control, scenario planning, and risk management.
- Use tools such as Smartsheet, Microsoft Project, or comparable platforms.
- Align senior stakeholders and functional experts without direct authority.
- Demonstrated leadership of at least one product launch from prelaunch planning through commercialization.
Nice to have
- Experience with a company’s first commercial launch
- Experience with oncology and/or rare disease therapies
About the company
Remix Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapies. The company is merging with Passage Bio and will operate as Remix Therapeutics.